{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:16:10Z","timestamp":1784200570153,"version":"3.55.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2026,8]]},"abstract":"\n Purpose:<\/jats:title>\n \n The performance of self-expanding stent graft (Gore\n \u00ae<\/jats:sup>\n Viabahn\n \u00ae<\/jats:sup>\n ) in femoropopliteal interventions has been proven through trials with long lesions. However, there are limited data on the incorporation of additional edge-protection to reduce focal edge stenosis. The aim of this study was to assess the clinical safety and efficiency of Viabahn\n \u00ae<\/jats:sup>\n stent graft incorporating additional edge-protection in the treatment of long femoropopliteal lesions [TransAtlantic Inter-Society Consensus (TASC) C\/D] in patients with symptomatic peripheral arterial disease.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n This is 2 centers, retrospective, observational, single-arm study. Patients with symptomatic (Rutherford category 2\u20136) de novo and restenosis TASC C\/D lesions of the femoropopliteal segment were treated with Viabahn\n \u00ae<\/jats:sup>\n stent graft. Additional edge-protection bare metal stent (BMS), drug-coated balloon (DCB), or drug-eluting stent (DES) were allowed at the proximal and distal edges of the Viabahn\n \u00ae<\/jats:sup>\n stent graft. The primary endpoint was the primary patency.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Between October 2019 and October 2022, 188 symptomatic patients with 198 limbs were treated (TASC D=68, 34%). The mean lesion length was 256\u00b1118\u2009mm, and 88% were total occlusion. Additional BMS, DCB, or DES were used at Viabahn\n \u00ae<\/jats:sup>\n edges in 24%, 16%, and 13% of cases, respectively. The mean follow-up was 12\u2009months. The primary patency rate at 12\u2009months was 70.8%. A significantly lower rate of primary patency was reported in the Viabahn\n \u00ae<\/jats:sup>\n \u2009+\u2009BMS group (54.3%) compared to Viabahn\n \u00ae<\/jats:sup>\n group (76.5%), Viabahn\n \u00ae<\/jats:sup>\n \u2009+\u2009DCB group (81.4%), and Viabahn\n \u00ae<\/jats:sup>\n \u2009+\u2009DES group (72.5%; p=0.01). The primary sustained clinical improvement rate was 85%. The Rutherford category assessment was significantly improved at last follow-up compared to baseline (p<0.0001). There were 2 cases of acute ischemia.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n The use of Viabahn\n \u00ae<\/jats:sup>\n stent graft in long lesions (TASC C\/D) with drug-coated devices as additional edge-protection seems to improve the results in the treatment of long and complex femoropopliteal lesions. These results reinforce the need for randomized clinical trials to assess the value of self-expanding stent graft for long femoropopliteal lesions.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Impact<\/jats:title>\n This study evaluates the clinical impact of the performance of a self-expanding stent graft (Gore\u00ae Viabahn\u00ae) in femoropopliteal lesions and demonstrates its safety and efficacy in the treatment of long and complex lesions. The results indicate that the combination of the Viabahn\u00ae with paclitaxel-eluting devices on its proximal and distal edges increases clinical improvement and decreases the incidence of restenosis. Overall, this study highlights the benefit of active therapy in the Viabahn\u00ae edges and supports its increased use in clinical practice to optimise long-term outcomes in long and complex femoropopliteal lesions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/15266028251335525","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:42:49Z","timestamp":1745559769000},"page":"2064-2071","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["One-Year Results of Endovascular Treatment of Long Femoropopliteal Lesions With Viabahn\n \u00ae<\/sup>\n Stent Graft"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-9764","authenticated-orcid":false,"given":"Bahaa","family":"Nasr","sequence":"first","affiliation":[{"name":"Univ Brest, INSERM, IMT-Atlantique, UMR 1011 LaTIM, Brest, France"},{"name":"Vascular and Endovascular Surgery Department, CHU Cavale Blanche, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Wiktor","sequence":"additional","affiliation":[{"name":"Vascular and Endovascular Surgery Department, CHU Cavale Blanche, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Goyault","sequence":"additional","affiliation":[{"name":"Department of Vascular and Oncological Interventional Radiology, Institut Cardiovasculaire de Strasbourg (ICS), Clinique Rhena, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gou\u00ebffic","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Paris Saint Joseph Hospital Group, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2023.08.067"},{"key":"e_1_3_2_3_2","first-page":"161","article-title":"Treatment strategies for extensive chronic SFA occlusions: indications and results","volume":"53","author":"Lensvelt MM","year":"2012","unstructured":"Lensvelt MM, Reijnen MM, Wallis De, Vries BM, et al Treatment strategies for extensive chronic SFA occlusions: indications and results. J Cardiovasc Surg. 2012;53(1 suppl 1):161\u2013170.","journal-title":"J Cardiovasc Surg"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58091293"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2012.07.015"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.01.128"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2018.03.046"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028221075227"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.07.099"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.12.066"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30152"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.10.004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2013.01.050"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1583\/14-4790R.1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-014-1024-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2008.06.020"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.09.013"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2022.05.046"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820965965"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2022.01.001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.01.065"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X241233528"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820960445"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.05.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054835"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2015.04.436"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2010.03.071"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2012.08.068"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.03.030"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1583\/13-4374MR.1"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.11.044"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251335525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028251335525","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251335525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:56:04Z","timestamp":1784199364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028251335525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/15266028251335525"],"URL":"https:\/\/doi.org\/10.1177\/15266028251335525","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}